THALES/TELIT-CINTERION
27.2.2024 09:01:30 CET | Business Wire | Press release
Telit Cinterion IoT modules featuring Thales Instant Connect can be remotely activated for cellular connectivity at the time of device installation or during in-field operation. This streamlines IoT deployments as it simplifies supply chain, device installation and maintenance, helping to keep IoT devices connected anywhere, and at all times. Aidon, a leader in smart metering solutions, is the first to benefit from this partnership and solution, deploying IoT modules and initial connectivity from a single vendor, Telit Cinterion.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240227054738/en/
credit > sergray
By integrating Thales technology into Telit Cinterion modules, enterprises can enjoy instant out-of-the-box connectivity activation irrespective of the grid of available mobile networks. The collaboration between the two companies on this innovative solution enables them to get their IoT connected products in the market quickly, allowing them to reap the benefits of digital transformation that is at the core of the IoT promise.
The way the solution works is that, at the end of device production or when it is deployed in the field, the Telit Cinterion module uses the initial connectivity provided by Thales Instant Connect, to download the target local connectivity from the network operators selected by the IoT service provider. This allows device manufacturers and service providers to postpone selecting a connectivity provider until after the device is manufactured and throughout the deployment process. It can also be used during in-field operation, enabling deployed devices to stay connected throughout unexpected cellular network outages. This flexibility is particularly beneficial in situations where the devices are deployed across different regions or countries, as it allows for seamless integration with local network operators.
“Helping our enterprise customers to quickly launch and monetize IoT is our mission at Telit Cinterion. Adding the Thales eSIM to our modules in combination with our SIM provisioning and global MVNO services to streamline the final connectivity provider selection is a game changer in the industry. This powerful solution delivers unparalleled adaptability to changing circumstances and simplifies supply chain and logistics because it is based on a single eSIM with Thales Instant Connect, which can be shipped anywhere in the world,” said Manish Watwani, Chief Marketing and Product Officer at Telit Cinterion.
“The IoT eSIM solution is an important innovation, ensuring production flexibility and connectivity of our smart meters, even in rural areas, and all without the need for physical handling of SIMs. The solution provides a true operator selection and provisioning at any stage of the product lifetime. It is improving our ability to get smart meters connected, stay connected and adapt to new metering as-a-service business models,” said Petri Ounila, Director, IoT Devices, Aidon.
“Thales aims to support IoT adopters and streamline device deployment with our eSIM with initial connectivity via Thales Instant Connect service. This simplifies and accelerates large scale IoT deployments for device makers, benefiting all stakeholders in the value chain. Thales is pleased to work with Telit Cinterion to support its success in cellular connectivity and speed up device deployment,” said Guillaume Lafaix, Senior Vice President Mobile Connectivity Solutions at Thales.
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations – connectivity, big data, artificial intelligence, cybersecurity and quantum technologies – to build a confident future crucial for the development of our societies. The Group provides its customers – businesses, organizations and governments – in the defense, aeronautics, space, transport, and digital identity and security domains with solutions, services and products that help them fulfill their critical role, consideration for the individual being the driving force behind all decisions.
Thales has 77,0001 employees in 68 countries. In 2022, the Group generated sales of €17.6 billion.
_______________________________
1 Excluding Transport business, which is being divested
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240227054738/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom